세계의 5-알파 환원효소 결핍증 시장 보고서(2025년)

5-alpha reductase deficiency is a disorder that impacts male sexual development, both preceding and during puberty. Individuals with this condition experience insufficient production of dihydrotestosterone, a crucial hormone for male sexual development.

The primary diagnostic methods for 5-alpha reductase deficiency include chromosome analysis, gene sequencing, hormone tests, imaging tests, and genetic screening, among others. Chromosome analysis is employed to determine the patient's chromosomal makeup, distinguishing between XX (Female) and XY (Male) chromosomes. Various treatments are available for 5-alpha reductase deficiency, including surgery, vaginoplasty, feminizing genitoplasty, hormone replacement therapy, and other interventions. End-users of these treatments include hospitals, specialty clinics, and other medical facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The 5-alpha reductase deficiency market research report is one of a series of new reports from The Business Research Company that provides 5-alpha reductase deficiency market statistics, including 5-alpha reductase deficiency industry global market size, regional shares, competitors with a 5-alpha reductase deficiency market share, detailed 5-alpha reductase deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the 5-alpha reductase deficiency industry. This 5-alpha reductase deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The 5-alpha reductase deficiency market size has grown strongly in recent years. It will grow from $1.4 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to research and development, regulatory landscape, healthcare infrastructure, increased awareness and education, health insurance coverage.

The 5-alpha reductase deficiency market size is expected to see strong growth in the next few years. It will grow to $2.15 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to innovations in therapeutics, genetic research advances, precision medicine, global health initiatives, integration of gene therapies. Major trends in the forecast period include advancements in treatment options, diagnostic innovations, patient-centric approaches, regulatory landscape, market access and affordability.

The forecast of 9.6% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to specialized enzyme inhibitors and hormonal therapeutics imported from India and Belgium, potentially increasing treatment costs for affected patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The escalating number of research and development endeavors in genomics is significantly contributing to the growth trajectory of the 5-alpha reductase deficiency market. Genomics, involving the comprehensive study of an individual's entire genome, including the interplay between genes and their environment, serves as a pivotal tool in diagnosing 5-alpha reductase deficiency by pinpointing specific genetic mutations responsible for the condition. Consequently, the surge in research and development activities within genomics is poised to play a crucial role in not only uncovering but also treating this disorder. As detailed in the 'Accelerating Access to Genomics for Global Health' report by the World Health Organization (WHO) in July 2022, the percentage of nations equipped to perform genomic surveillance surged from 54% to 68% between March 2021 and January 2022. Therefore, the burgeoning research and development efforts in genomics are forecasted to be a primary driver propelling the 5-alpha reductase deficiency market.

The mounting prevalence of genetic and rare diseases stands poised to propel the growth trajectory of the 5-alpha reductase deficiency market in the forthcoming years. Genetic and rare diseases, arising from alterations in an individual's genes and being uncommon within the general populace, highlight the intricate role of genetic factors in human development, especially concerning sexual differentiation, exemplified by 5-alpha reductase deficiency. As noted in November 2022 by the Australian Government Department of Health, approximately 7,000 rare illnesses, either fatal or severely disabling, exist. These rare diseases impact about 8% of Australians, totaling around 2 million individuals, with roughly 80% being genetic in nature. Consequently, the escalating prevalence of genetic and rare diseases constitutes a pivotal factor propelling the 5-alpha reductase deficiency market.

The emergence of innovative genetic testing methodologies for diagnosing rare diseases constitutes a key trend in the 5-alpha reductase deficiency market. Leading entities operating within this domain are directing their efforts toward developing pioneering genetic testing solutions that efficiently diagnose rare conditions such as 5-alpha reductase deficiency, particularly in their nascent stages. These advancements in diagnostics not only offer a competitive advantage to major market players but also enhance their position in the market. For instance, in June 2022, Avesthagen Limited, a US-based integrated systems biology platform company, unveiled its latest genetic testing portfolio. The genome panels encompassed in this portfolio present highly specialized, disease-centric analyses tailored for rare genetic diseases, thereby showcasing significant strides in the diagnostic landscape.

Leading companies in the 5-alpha reductase deficiency market are focusing on the development of advanced products, such as consumer-initiated genetic tests, enabling individuals to access personal genetic information privately and directly, without requiring a healthcare provider's referral. A consumer-initiated genetic test allows individuals to order genetic testing from a laboratory or testing company independently, providing insights into genetic predispositions, ancestry, or health-related traits without the need for a healthcare provider's involvement. For example, in July 2023, Quest Diagnostics, a US-based diagnostic information services provider, introduced Genetic Insights, a consumer-initiated genetic test. This new product helps individuals evaluate their risk of developing certain hereditary health conditions. It offers advanced technology, personalized health reports, and access to genetic counseling. By analyzing a saliva sample, Genetic Insights assesses 36 genes to identify risks for nearly two dozen hereditary conditions, including breast and colon cancer, heart and blood disorders, and carrier status for conditions such as cystic fibrosis, sickle cell anemia, and Tay-Sachs disease. The test is designed to address gaps in existing consumer genetic tests and utilizes state-of-the-art next-generation sequencing (NGS) technology, which can analyze thousands of DNA variants in disease-related genes and examines more regions of a person's genome compared to traditional microarray testing.

In April 2023, Blue Water Vaccines Inc., a US-based biopharmaceutical firm, completed the acquisition of ENTADFI (finasteride/tadalafil) from Veru Inc. for an approximate sum of $100 million. This acquisition significantly expands the company's scope across various pharmaceutical sectors. By acquiring ENTADFI, Blue Water gains entry into the commercial domain while also mitigating expenditure and securing crucial revenue streams for the vaccine candidate pipeline. Despite this expansion, Blue Water remains steadfast in its primary mission of aiding individuals in need and is eager to enhance this asset and the pipeline for patients worldwide. Veru Inc. functions as a US-based biopharmaceutical company.

Major companies operating in the 5-alpha reductase deficiency market include F. Hoffmann-La Roche Ltd., Sanofi SA, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Alma Lasers Ltd., Viveve Medical Inc., Fotona d.o.o, Almirall SA, Hologic Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Mallinckrodt Pharmaceuticals, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Roivant Sciences Ltd., Sanofi Genzyme, Shionogi & Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Vertex Pharmaceuticals Incorporated, Zoetis Inc., Cadila Healthcare Limited, Endo International plc

North America was the largest region in the 5-alpha reductase deficiency market in 2024. The regions covered in the 5-alpha reductase deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the 5-alpha reductase deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The 5-alpha reductase deficiency market includes revenues earned by entities by providing ultrasound screening diagnosis and surgical procedures to treat 5-alpha reductase deficiencies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

5-Alpha Reductase Deficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on 5-alpha reductase deficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for 5-alpha reductase deficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The 5-alpha reductase deficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Diagnosis: Chromosome Analysis; Gene Sequencing; Hormone Tests; Imaging Tests; Genetic Screening; Other Diagnosis
• 2) By Treatment: Surgery; Vaginoplasty; Feminizing Genitoplasty; Hormone Replacement Therapy; Other Treatments
• 3) By End-Users: Hospitals; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Chromosome Analysis: Karyotyping; Fluorescence In Situ Hybridization (FISH)
• 2) By Gene Sequencing: Targeted Gene Panels; Whole Exome Sequencing
• 3) By Hormone Tests: Testosterone Levels; Dihydrotestosterone (DHT) Levels
• 4) By Imaging Tests: Ultrasound; MRI
• 5) By Genetic Screening: Carrier Testing; Newborn Screening
• 6) By Other Diagnosis: Clinical Evaluation; Family History Assessment
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Sanofi SA; Pfizer Inc.; GlaxoSmithKline plc; Novartis AG; Bayer AG; Eli Lilly and Company; Alma Lasers Ltd.; Viveve Medical Inc.; Fotona d.o.o; Almirall SA; Hologic Inc.; Gilead Sciences Inc.; Johnson & Johnson Services Inc.; Mallinckrodt Pharmaceuticals; Novo Nordisk A/S; Regeneron Pharmaceuticals Inc.; Roivant Sciences Ltd.; Sanofi Genzyme; Shionogi & Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; UCB S.A.; Vertex Pharmaceuticals Incorporated; Zoetis Inc.; Cadila Healthcare Limited; Endo International plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. 5-Alpha Reductase Deficiency Market Characteristics

3. 5-Alpha Reductase Deficiency Market Trends And Strategies

4. 5-Alpha Reductase Deficiency Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global 5-Alpha Reductase Deficiency Growth Analysis And Strategic Analysis Framework

• 5.1. Global 5-Alpha Reductase Deficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global 5-Alpha Reductase Deficiency Market Growth Rate Analysis
• 5.4. Global 5-Alpha Reductase Deficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global 5-Alpha Reductase Deficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global 5-Alpha Reductase Deficiency Total Addressable Market (TAM)

6. 5-Alpha Reductase Deficiency Market Segmentation

• 6.1. Global 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chromosome Analysis
• Gene Sequencing
• Hormone Tests
• Imaging Tests
• Genetic Screening
• Other Diagnosis
• 6.2. Global 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Vaginoplasty
• Feminizing Genitoplasty
• Hormone Replacement Therapy
• Other Treatments
• 6.3. Global 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users
• 6.4. Global 5-Alpha Reductase Deficiency Market, Sub-Segmentation Of Chromosome Analysis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Karyotyping
• Fluorescence In Situ Hybridization (FISH)
• 6.5. Global 5-Alpha Reductase Deficiency Market, Sub-Segmentation Of Gene Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Gene Panels
• Whole Exome Sequencing
• 6.6. Global 5-Alpha Reductase Deficiency Market, Sub-Segmentation Of Hormone Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Testosterone Levels
• Dihydrotestosterone (DHT) Levels
• 6.7. Global 5-Alpha Reductase Deficiency Market, Sub-Segmentation Of Imaging Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ultrasound
• MRI
• 6.8. Global 5-Alpha Reductase Deficiency Market, Sub-Segmentation Of Genetic Screening, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Carrier Testing
• Newborn Screening
• 6.9. Global 5-Alpha Reductase Deficiency Market, Sub-Segmentation Of Other Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinical Evaluation
• Family History Assessment

7. 5-Alpha Reductase Deficiency Market Regional And Country Analysis

• 7.1. Global 5-Alpha Reductase Deficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global 5-Alpha Reductase Deficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific 5-Alpha Reductase Deficiency Market

• 8.1. Asia-Pacific 5-Alpha Reductase Deficiency Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China 5-Alpha Reductase Deficiency Market

• 9.1. China 5-Alpha Reductase Deficiency Market Overview
• 9.2. China 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India 5-Alpha Reductase Deficiency Market

• 10.1. India 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan 5-Alpha Reductase Deficiency Market

• 11.1. Japan 5-Alpha Reductase Deficiency Market Overview
• 11.2. Japan 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia 5-Alpha Reductase Deficiency Market

• 12.1. Australia 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia 5-Alpha Reductase Deficiency Market

• 13.1. Indonesia 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea 5-Alpha Reductase Deficiency Market

• 14.1. South Korea 5-Alpha Reductase Deficiency Market Overview
• 14.2. South Korea 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe 5-Alpha Reductase Deficiency Market

• 15.1. Western Europe 5-Alpha Reductase Deficiency Market Overview
• 15.2. Western Europe 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK 5-Alpha Reductase Deficiency Market

• 16.1. UK 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany 5-Alpha Reductase Deficiency Market

• 17.1. Germany 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France 5-Alpha Reductase Deficiency Market

• 18.1. France 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy 5-Alpha Reductase Deficiency Market

• 19.1. Italy 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain 5-Alpha Reductase Deficiency Market

• 20.1. Spain 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe 5-Alpha Reductase Deficiency Market

• 21.1. Eastern Europe 5-Alpha Reductase Deficiency Market Overview
• 21.2. Eastern Europe 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia 5-Alpha Reductase Deficiency Market

• 22.1. Russia 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America 5-Alpha Reductase Deficiency Market

• 23.1. North America 5-Alpha Reductase Deficiency Market Overview
• 23.2. North America 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA 5-Alpha Reductase Deficiency Market

• 24.1. USA 5-Alpha Reductase Deficiency Market Overview
• 24.2. USA 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada 5-Alpha Reductase Deficiency Market

• 25.1. Canada 5-Alpha Reductase Deficiency Market Overview
• 25.2. Canada 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America 5-Alpha Reductase Deficiency Market

• 26.1. South America 5-Alpha Reductase Deficiency Market Overview
• 26.2. South America 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil 5-Alpha Reductase Deficiency Market

• 27.1. Brazil 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East 5-Alpha Reductase Deficiency Market

• 28.1. Middle East 5-Alpha Reductase Deficiency Market Overview
• 28.2. Middle East 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa 5-Alpha Reductase Deficiency Market

• 29.1. Africa 5-Alpha Reductase Deficiency Market Overview
• 29.2. Africa 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. 5-Alpha Reductase Deficiency Market Competitive Landscape And Company Profiles

• 30.1. 5-Alpha Reductase Deficiency Market Competitive Landscape
• 30.2. 5-Alpha Reductase Deficiency Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. 5-Alpha Reductase Deficiency Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Eli Lilly and Company
• 31.3. Alma Lasers Ltd.
• 31.4. Viveve Medical Inc.
• 31.5. Fotona d.o.o
• 31.6. Almirall SA
• 31.7. Hologic Inc.
• 31.8. Gilead Sciences Inc.
• 31.9. Johnson & Johnson Services Inc.
• 31.10. Mallinckrodt Pharmaceuticals
• 31.11. Novo Nordisk A/S
• 31.12. Regeneron Pharmaceuticals Inc.
• 31.13. Roivant Sciences Ltd.
• 31.14. Sanofi Genzyme
• 31.15. Shionogi & Co. Ltd.

32. Global 5-Alpha Reductase Deficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The 5-Alpha Reductase Deficiency Market

34. Recent Developments In The 5-Alpha Reductase Deficiency Market

35. 5-Alpha Reductase Deficiency Market High Potential Countries, Segments and Strategies

• 35.1 5-Alpha Reductase Deficiency Market In 2029 - Countries Offering Most New Opportunities
• 35.2 5-Alpha Reductase Deficiency Market In 2029 - Segments Offering Most New Opportunities
• 35.3 5-Alpha Reductase Deficiency Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer